$0.18
-0.02 (-9.38%)
VNRX News2 articles
VolitionRx Shares Jump 97% on Sepsis Test Validation
VolitionRx shares surged 97.5% premarket after clinical validation of its Nu.Q NETs sepsis biomarker. The study, published in Critical Care Medicine, boosted investor confidence.
Tonix Pharma Surges on Promising Lyme Antibody Data; Phase 2 Trial Eyed for 2027
Tonix Pharmaceuticals shares rose after new Phase 1 modeling data for its Lyme antibody TNX-4800 showed six-month protection with two doses. A Phase 2 trial is targeted for 2027.